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Abstract
Objective
To investigate whether enlarged perivascular spaces (PVS) within the basal ganglia or deep
cerebral white matter are risk factors for intracranial hemorrhage in patients taking oral anti-
coagulants (OACs), independent of established clinical and radiologic risk factors, we con-
ducted a post hoc analysis of Clinical Relevance of Microbleeds in Stroke (CROMIS-2) (atrial
fibrillation [AF]), a prospective inception cohort study.
Methods
Patients with atrial fibrillation and recent TIA or ischemic stroke underwent standardized MRI
prior to starting OAC. We rated basal ganglia PVS (BGPVS) and centrum semiovale PVS
(CSOPVS), cerebral microbleeds (CMBs), white matter hyperintensities, and lacunes. We
dichotomized the PVS rating using a threshold of >10 PVS in the relevant region of either
cerebral hemisphere. The primary outcome was symptomatic intracranial hemorrhage (sICH).
We identified risk factors for sICH using Cox regression.
Results
A total of 1,386 participants with available clinical and imaging variables were followed up for a
mean of 2.34 years; 14 sICH occurred (11 intracerebral). In univariable analysis, diabetes, CMB
presence, lacune presence, and >10 BGPVS, but not CSOPVS, were associated with sICH. In a
multivariable model incorporating all variables with significant associations in univariable
analysis, >10 BGPVS (hazard ratio [HR] 8.96, 95% [CI] 2.41–33.4, p = 0.001) and diabetes
(HR 3.91, 95% CI 1.34–11.4) remained significant risk factors for sICH.
Conclusion
Enlarged BGPVS might be a novel risk factor for OAC-related ICH. The strength of this
association and potential use in predicting ICH in clinical practice should be investigated in
larger cohorts.
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Within the brain, the perivascular space (PVS) is the com-
partment bounded by the wall of penetrating cerebral blood
vessels and the glia limitans, which might facilitate fluid cir-
culation and clearance of soluble waste, including β-amyloid
(Aβ), from brain parenchyma.1–3 In age and disease, PVS may
enlarge and become MRI-visible, as fluid-filled structures
most easily assessed within the basal ganglia and the centrum
semiovale white matter. Cross-sectional studies of in-
tracerebral hemorrhage (ICH) survivors have associated en-
larged basal ganglia PVS (BGPVS) with deep ICH, increased
white matter hyperintensity volume, and deep cerebral
microhemorrhages, and enlarged centrum semiovale PVS
(CSOPVS) with lobar ICH and cerebral amyloid angiopathy
(CAA).4–6 In cognitively impaired patients, BGPVS are as-
sociated with hypertension, deep CMBs, and lacunes, and
CSOPVS with lobar CMBS, cortical superficial siderosis, and
Alzheimer disease.7–9
Together, these data suggest that BGPVS might be markers
of deep perforator arteriopathy, and CSOPVS of Aβ pa-
thology, including CAA. PVS might therefore also indicate
increased ICH risk. A prospective study of patients with
TIA or ischemic stroke found an association between >20
BGPVS in either hemisphere and incident ICH, though this
was not statistically significant when adjusted for vascular
risk factors.10 We investigated this question in patients with
atrial fibrillation (AF) taking oral anticoagulants (OACs)
after ischemic stroke or TIA. We hypothesized that BGPVS
and CSOPVS would be associated with anticoagulant-
related intracranial hemorrhage (OAC-ICH), independent
of other markers of cerebral small vessel disease linked to
OAC-ICH, notably cerebral microbleeds (CMBs) and
white matter hyperintensities.11,12
Methods
Study design
We conducted a post hoc analysis of the Clinical Relevance of
Microbleeds in Stroke (CROMIS-2) (AF) study, a multi-
center prospective inception cohort study of the relationship
between CMBs and anticoagulant-related symptomatic in-
tracranial hemorrhage (sICH). The design, full description of
the cohort, and primary results of this study have been pub-
lished elsewhere.11 Briefly, we recruited adult patients with AF
initiating oral anticoagulation after recent ischemic stroke or
TIA from 79 hospitals in the United Kingdom and 1 in the
Netherlands between August 2011 and July 2015. MRI was
performed at baseline according to a standardized protocol,
including axial T1- and T2-weighted, coronal fluid-attenuated
inversion recovery (FLAIR), diffusion-weighted, and T2*-
weighted gradient-recalled echo sequences. To reduce selec-
tion bias, imaging was performed after study enrollment, and
we only enrolled participants whose responsible clinician had
already decided to treat with an anticoagulant. We followed
up participants for 24 months using multiple overlapping
methods, including postal questionnaires, telephone inter-
views, and hospital episode statistics. The primary outcome
was sICH, defined as brain imaging evidence of nontraumatic
spontaneous intracranial hemorrhage with appropriate clini-
cal symptoms.
Neuroimaging analysis
We analyzed participants’MRIs for markers of cerebral small
vessel disease according to STRIVE (Standards for Reporting
Vascular Changes on Neuroimaging) definitions.13 Trained
research fellows (J.G.B., D.W., G.B., H.D.) performed ratings
blinded to the occurrence of sICH during follow-up, using
validated rating scales where available. One of 2 raters (G.B.,
H.D.) rated PVS at the level of the basal ganglia and centrum
semiovale separately, using a 5-level scale that assigns a score
of 0 to no visible PVS, 1 to 1–10, 2 to 11–20, 3 to >21–40, and
4 to >40 PVS.14 We rated each hemisphere, unless prevented
by the presence of a focal lesion, and used the higher of the 2
values. We rated CMBs using the Microbleed Anatomical
Rating Scale15 and white matter hyperintensities using the
Age-Related White Matter Changes (ARWMC) scale
(D.W.).16 We identified and counted lacunes (G.B., H.D.).
Given the possibility that enlarged PVS might predominantly
reflect cerebral atrophy, 1 of 2 raters (G.B., J.G.B.) rated each
participant’s imaging using the simplified Pasquier scale,17
which quantifies the global severity of cortical atrophy (GCA)
on a 4-level scale (0: no atrophy, 1: sulcal widening, 2: gyral
volume loss, 3: “knife-blade” atrophy). We used axial T1 or
FLAIR images for rating if available, and inverted axial T2
images if not. When a significant focal lesion was present, we
rated the nonlesioned hemisphere.
When more than 1 rater rated a marker, we assessed interrater
agreement on a random sample using Cohen kappa, weighted
for ordinal variables.
Statistical analysis
We investigated the association between enlarged PVS and
the hazard of sICH using Cox regression. As well as BGPVS
Glossary
Aβ = β-amyloid; ARWMC = Age-Related White Matter Changes; AF = atrial fibrillation; BGPVS = basal ganglia perivascular
spaces; CAA = cerebral amyloid angiopathy; CI = confidence interval; CMB = cerebral microbleed; CROMIS-2 = Clinical
Relevance of Microbleeds in Stroke; CSOPVS = centrum semiovale perivascular spaces; FLAIR = fluid-attenuated inversion
recovery; GCA = global severity of cortical atrophy; HR = hazard ratio; ICH = intracerebral hemorrhage; OAC = oral
anticoagulant; PVS = perivascular space; sICH = symptomatic intracranial hemorrhage.
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and CSOPVS, we prespecified age, sex, clinical history of
diabetes mellitus, and clinical history of hypertension as
clinical independent variables and ARWMC score, CMBs,
lacunes, and GCA as additional imaging independent var-
iables. We chose not to include cortical superficial siderosis
due to its very low prevalence in our study population.
Using a predetermined threshold previously associated
with the presence of other small vessel disease markers14
and incorporated into a validated composite small vessel
disease score as representing moderate to severe PVS,18 we
dichotomized PVS counts in our analysis as 0–10 or >10,
equivalent to a PVS score of 0–1 and 2–4, respectively. We
dichotomized CMBs and lacunes as present or absent. We
included the ARWMC score as a continuous variable. As
very few participants received a GCA rating of 3, we
combined categories 2 and 3 to give a 3-level ordinal var-
iable comprising no atrophy (0), minor atrophy (1), and
moderate to severe atrophy (2–3). To reduce the risk of
overfitting, we initially performed univariable analysis for
each variable, and included only variables with an associa-
tion at the 20% level in our final multivariable analysis. We
checked the proportional hazards assumption using visual
inspection of log-log plots of the log cumulative hazard
against log time and through postestimation tests based on
Schoenfeld residuals. We summarized our results graphi-
cally using plots of the Kaplan-Meier failure (1 − survival)
function. Statistical analysis was performed using Stata
version 15.0.
Standard protocol approvals, registrations,
and patient consents
The UK National Health Service Research Ethics Committee
approved the CROMIS-2 study. Patients with capacity pro-
vided written informed consent. We obtained proxy written
informed consent if patients lacked capacity to consent, fol-
lowing relevant local legislation.
Data availability
We will share anonymized data on reasonable request, fol-
lowing consideration by the CROMIS-2 steering committee
and execution of a data sharing agreement. Requests should
be submitted to d.werring@ucl.ac.uk.
Results
The primary analysis of the CROMIS-2 (AF) study included
1,447 participants who met the main study inclusion criteria
and had follow-up data available. Of these, 1,386 participants
(95.8%) had all additional variables of interest needed for this
secondary analysis (figure 1). Participants excluded from our
secondary analysis due to missing variables were more likely
to be female and have hypertension. As other variables were
comparable (table 1) and the overall proportion of missing
data was very low, we performed a complete case analysis.
During 3,251 participant-years of follow-up, 14 sICH oc-
curred (11 intracerebral, 2 subdural, 1 subarachnoid). The
Figure 1 Study flowchart
CROMIS-2 (AF) = Clinical Relevance of
Microbleeds in Stroke (atrial fibrillation);
FLAIR = fluid-attenuated inversion re-
covery; HTN = hypertension.
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median time from anticoagulation initiation to sICH was 272
days (interquartile range 211–657). Of the 10 intracerebral
hemorrhages for which data on location were available, 2 were
deep, 4 were infratentorial, and 4were lobar. Table 2 summarizes
the clinical and radiologic characteristics of participants with and
without sICH during follow-up. Interrater agreement for di-
chotomized PVS score was excellent (k = 0.82) within the basal
ganglia and substantial (k = 0.80) within the centrum semiovale
(n = 50). Agreement for GCA rating was moderate (k = 0.53; n
= 100), comparable to that in other existing literature.19 We
observed a weak correlation between GCA and BGPVS grade
(Spearman ρ 0.17, 95% confidence interval [CI] 0.12–0.22), but
not CSOPVS grade (r = 0.04, 95% CI −0.01 to 0.01).
Univariable Cox regression showed associations between
BGPVS, diabetes, lacune presence, and CMB presence and
sICH (table 3).We found no evidence of an association between
CSOPVS and sICH. In a multivariable model incorporating
diabetes, BGPVS, CMB presence, and lacune presence, we
found strong evidence of an association with sICH for enlarged
BGPVS and diabetes, and weak evidence of an association for
CMB presence. No evidence of an association was found for
lacune presence. Figure 2 shows the cumulative incidence of
sICH during study follow-up for participants with 0–10 and >10
BGPVS. The absolute rate of sICH in participants with >10
BGPVS was 1.38/100 participant-years (95% CI 0.69–2.47),
compared to 0.12/100 participant-years (95%CI 0.025–0.36) in
participants with 0–10 BGPVS.
Given the number of variables included in our multivariable
model relative to the number of outcome events, we per-
formed additional sensitivity analyses, testing each combina-
tion of BGPVS presence and diabetes, CMB presence, or
lacune presence individually (table 4). The result of each
analysis was similar to that of the main multivariable model.
We also undertook a sensitivity analysis to investigate the
effect of dichotomizing PVS as 0–20 or >20, rather than 0–10
or >10. Using this threshold, we did not find an association
between higher BGPVS or CSOPVS counts and sICH
(BGPVS: hazard ratio [HR] 1.0, 95% CI 0.13–7.5; CSOPVS:
HR 1.3, 95% CI 0.36–4.6); however, few participants in our
study had counts >20 in either location (table 2), and CIs for
both estimates were wide.
For each model, visual inspection of log-log plots suggested
no violation of the proportional hazards assumption. Al-
though postestimation tests provided some evidence that the
assumption was violated for hypertension (p = 0.037), the
estimate of the hazard ratio for sICH for hypertension pro-
vided no evidence for an association, and hypertension was
not included in our multivariable model.
Discussion
Our main finding is an association between enlarged PVS
within the basal ganglia, but not centrum semiovale, and
OAC-ICH, independent of major vascular risk factors and
other markers of cerebral small vessel disease. The estimate
and 95% CI of the HR was consistent with a clinically
meaningful association, and was highly statistically significant,
though it lacked precision. Although preliminary, our finding
raises the possibility that enlarged BGPVS might be a clini-
cally relevant marker of OAC-ICH risk. Other studies have
provided supportive observational evidence that in-
corporating small vessel disease markers, specifically CMB
presence andWMH severity, can improve the performance of
clinical risk scores for ICH,11,12 and the current analysis
suggests that incorporating BGPVS status into these scores
might usefully be investigated. An advantage of BGPVS status
as a marker might be that it can be quantified on axial T2
imaging, a routine component of nearly all clinical brain MRI.
Our findings add to the evidence linking enlarged PVS to
cerebrovascular disease, but why PVS enlargement might
occur in the setting of hemorrhage-prone cerebral small vessel
disease remains unclear. PVS enlargement might reflect ex-
travasation of fluid across damaged small vessel walls, possibly
compounded by recruitment of inflammatory cells to the
PVS, where they might promote further loss of blood–brain
barrier integrity and impair perivascular fluid transport.20 In
Table 1 Characteristics of study population
Characteristics Included (n = 1,386) Excluded (n = 61)
Age, y 75.8 (10.4) 78.2 (9.2)
Female sex 575 (41.5) 36 (59.0)
Hypertension 876 (63.2) 30/39 (76.9)
Diabetes 229 (16.5) 13/59 (22.03)
>10 BGPVS 363 (26.2) 14/48 (29.2)
>10 CSOPVS 665 (48.0) 23/48 (47.9)
Lacune presence 286 (20.6) 9/41 (22.0)
CMB presence 288 (20.8) 16 (26.2)
ARWMC score 1 (0–3) 1 (0–3)
cSS presence 5 (0.35) 0 (0)
GCA score
0 461 (33.3) 17/59 (28.8)
1 613 (44.2) 29/59 (49.2)
2–3 312 (22.5) 13/59 (22.0)
sICH during follow-up 14 (1) 0 (0)
Abbreviations: ARWMC = Age-RelatedWhiteMatter Changes; BGPVS = basal
ganglia perivascular spaces; CMB = cerebral microhemorrhage; CSOPVS =
centrum semiovale perivascular spaces; cSS = cortical superficial siderosis;
GCA = global severity of cortical atrophy; sICH = symptomatic intracranial
hemorrhage.
Comparison of characteristics of participants included in analysis to those
excluded for missing at least 1 variable. Values show prevalence (%) for
categorical variables and mean (SD) or median (interquartile range) for
continuous variables.
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CAA, perivascular aggregation of Aβ may also impair drain-
age,21 but this is less likely to mediate the association between
BGPVS and ICH we observed. It is possible that more
advanced cerebral small vessel disease might lead directly to
PVS enlargement through ischemic brain atrophy. We con-
sider this less likely, as we corrected for a measure of overall
cerebral atrophy, and observed an association that was in-
dependent of other cerebral small vessel disease markers,
more consistent with BGPVS enlargement being a sensitive
marker or early feature of cerebral small vessel disease. Finally,
the association between BGPVS and ICH might be mediated
by a shared underlying mechanism. For example, arterial
stiffening has recently been associated with BGPVS,22 ad-
justed for major vascular risk factors, and also with deep ICH
cross-sectionally and new CMB formation prospectively.23,24
By reducing damping of the cardiac impulse and increasing
transmission of pulsatile force to small cerebral arteries,25
arterial stiffening might increase ICH risk, and promote PVS
formation by altering small vessel pulsatility, thought to be a
key driver of perivascular fluid transport.26,27
Unexpectedly, we did not find an association between
CSOPVS and sICH, despite evidence linking CSOPVS to
CAA. We considered whether CSOPVS might simply be
more difficult to measure reliably than BGPVS, leading to
increased statistical noise and difficulty in detecting any as-
sociations that do exist, but our excellent interrater reliability
for both BGPVS and CSOPVS argues against this. More likely
explanations include the low specificity of the association
between CSOPVS and CAA, as CSOPVS enlargement also
occurs in Alzheimer disease without clinical CAA, and the low
proportion of our study population (3%) who met modified
Boston criteria for CAA, probably because such patients are
not generally viewed as eligible for anticoagulation. Finally,
differences in regional vascular anatomy might contribute.
Whereas the hemispheric white matter is supplied by pene-
trating branches of distal cortical arteries, the basal region of
the brain is supplied by small perforating arteries that arise
directly from large cerebral arteries. These vessels are there-
fore exposed to higher peak blood pressures,28 and so to the
effects of systemic hypertension and, potentially, arterial
stiffening. BGPVS enlargement might therefore be a more
sensitive marker of these processes than CSOPVS.
As a secondary analysis of CROMIS-2 (AF), our study has
methodologic strengths: this was a large, multicenter pro-
spective inception cohort study, recruiting a population sim-
ilar in age, prevalence of vascular risk factors, and stroke
severity to the overall case mix of UK stroke units.29 We
obtained a >97% follow-up rate, and sICH events were ad-
judicated centrally without knowledge of CMB or PVS status.
The MRI protocol was standardized between sites, and im-
aging markers were rated blinded to sICH during follow-up.
We obtained substantial or excellent interrater agreement for
key small vessel disease markers.
Our study has limitations. Most importantly, as a post hoc
analysis, our results should be considered hypothesis-
generating. The need for verification of our findings in an
independent cohort is emphasized by the low number of
Table 2 Characteristics of patients with and without
symptomatic intracranial hemorrhage (sICH)
Characteristics No sICH (n = 1,372) sICH (n = 14)
Age, y 75.8 (10.4) 78.6 (10.5)
Female sex 570 (41.6) 5 (35.7)
Hypertension 868 (63.3) 8 (57.1)
Diabetes 223 (16.3) 6/14 (42.9)
>10 BGPVS 352 (25.7) 11 (78.6)
BGPVS count
0 62 (4.5) 0 (0)
1–10 958 (69.8) 3 (21.4)
11–20 247 (18.0) 10 (71.4)
21–40 86 (6.3) 1 (7.1)
>40 19 (1.4) 0 (0)
>10 CSOPVS 658 (48.0) 7 (50.0)
CSOPVS count
0 80 (5.8) 0 (0.0)
1–10 634 (46.2) 7 (50.0)
11–20 421 (30.7) 4 (28.6)
21–40 197 (14.4) 3 (21.4)
>40 40 (2.9) 0 (0.0)
Lacune presence 280 (20.4) 6 (42.9)
CMB presence 281 (20.5) 7 (50.0)
CMB distribution
Deep 113 (8.2) 1 (7.1)
Lobar 102 (7.4) 3 (21.4)
Mixed 66 (4.8) 3 (21.4)
ARWMC score 1 (0–3) 1.5 (0–5)
cSS presence 4 (0.3) 1 (7.1)
GCA score
0 455 (33.2) 6 (42.9)
1 607 (44.2) 6 (42.9)
2–3 310 (22.6) 2 (14.3)
Abbreviations: ARWMC = Age-RelatedWhite Matter Changes; BGPVS = basal
ganglia perivascular spaces; CMB = cerebral microhemorrhage; CSOPVS =
centrum semiovale perivascular spaces; cSS = cortical superficial siderosis;
GCA = global severity of cortical atrophy.
Comparison of characteristics of participants included in analysis with and
without sICH during follow-up. Values show prevalence (%) for categorical
variables and mean (SD) or median (interquartile range) for continuous
variables.
e2196 Neurology | Volume 95, Number 16 | October 20, 2020 Neurology.org/N
outcome events observed, although we attempted to limit
overfitting of our multivariable regression model by using a
variable-selection procedure, and undertook additional sen-
sitivity analyses. We included a clinical history of hypertension
as an independent variable in our analysis, but we lacked data
on BP control prior to or during the study, as well as details of
anticoagulation control intensity for warfarin-treated patients,
and adherence to anticoagulation for all participants. As eli-
gibility for anticoagulation was an inclusion criterion for the
study, our cohort might not be fully representative of the
overall population of patients with AF in whom anti-
coagulation is considered, and although study-specific
Table 3 Associations between variables and symptomatic intracranial hemorrhage
Characteristics Univariable HR (95% CI) p Value Multivariable HR (95% CI) p Value
Age 1.04 (0.98–1.09) 0.22 NA NA
Female sex 0.82 (0.27–2.43) 0.72 NA NA
Hypertension 0.79 (0.28–2.29) 0.67 NA NA
Diabetes 3.88 (1.35–11.2) 0.012 3.91 (1.34–11.4) 0.012
>10 BGPVS 10.8 (3.01–38.7) 0.000 8.96 (2.41–33.4) 0.001
>10 CSOPVS 1.06 (0.37–3.01) 0.92 NA NA
Lacune presence 2.97 (1.03–8.57) 0.044 1.54 (0.52–4.59) 0.43
CMB presence 3.80 (1.33–10.8) 0.013 2.61 (0.90–7.54) 0.077
ARWMC score 1.07 (0.86–1.34) 0.55 NA NA
GCA score 1 0.76 (0.25–2.37) 0.64 NA NA
GCA score 2–3 0.52 (0.11–2.59) 0.43 NA NA
Abbreviations: ARWMC = Age-Related White Matter Changes; BGPVS = basal ganglia perivascular spaces; CI = confidence interval; CMB = cerebral micro-
hemorrhage; CSOPVS = centrum semiovale perivascular spaces; GCA = global severity of cortical atrophy; HR = hazard ratio.
HRs (with 95% CI) in univariable analysis are shown for each study variable. Multivariable HRs refer to a model incorporating all variables with p < 0.2 in
univariable analysis.
Figure 2 Cumulative probability of symptomatic intracranial hemorrhage by basal ganglia (BG) perivascular space (PVS)
rating
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imaging was performed after the decision to treat with anti-
coagulation was made, we cannot exclude the possibility that
patient selection to our studymay have been influenced by the
results of imaging already performed as part of clinical care.
The generalizability of our result may be further affected by
our predominantly (95%) Caucasian study population, and
the low proportion of patients taking direct oral anticoagu-
lants (37%), which are increasingly preferred to warfarin in
clinical practice due to their lower risk of ICH. Of the 14 ICH
events observed in our study, 12 were in warfarin-treated
patients.
As well as validating our findings, further study in a large in-
dependent cohort is needed to allow precise estimation of the
strength of the association between BGPVS andOAC-ICH, and
investigation of its association with BGPVS count or score,
rather than the dichotomized rating used in this study.We failed
to observe an association between >20 BGPVS and sICH, in
contrast to a previous study,10 which we attribute to the low
prevalence of higher PVS counts in our study and the small
number of outcome events observed. However, the relationship
between BGPVS count and sICH might also be nonlinear,
showing a threshold effect, and larger, better-powered studies
might clarify this. Such studies might also investigate the re-
lationship between PVS and different locations of sICH (for
example, lobar vs deep/infratentorial intracerebral haemor-
rhage, or intracerebral vs subdural or subarachnoid hemor-
rhage), which have different biological mechanisms.
The clinical importance of our finding will depend on whether
adding BGPVS status to existing ICH risk models can im-
prove their performance, which we chose not to investigate in
our cohort due to the risk of overfitting, and clarification of
whether BGPVS are also associated with ischemic stroke, and
the strength of this association, if present, relative to that with
ICH. This information is needed to establish whether BGPVS
status should influence the selection of pharmacologic and
nonpharmacologic treatments for stroke prevention in pa-
tients with AF in clinical practice. Large-scale global collab-
oration between cohort studies of OAC-related ICH, such as
the Microbleeds International Collaborative Network,30
might provide a means by which to investigate these unan-
swered questions.
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Table 4 Sensitivity analyses
Model Multivariable HR (95% CI)
1
>10 BGPVS 11.5 (3.20–41.3)
Diabetes 4.37 (1.51–12.6)
2
>10 BGPVS 9.46 (2.6–34.2)
CMB presence 2.84 (0.99–8.17)
3
>10 BGPVS 9.55 (2.60–35.1)
Lacune presence 1.77 (0.60–5.20)
Abbreviations: BGPVS = basal ganglia perivascular spaces; CI = confidence
interval; CMB = cerebral microhemorrhage; HR = hazard ratio.
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